Ausgabe 5/2022
Inhalt (13 Artikel)
Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?
Christian A. Schneider, Roman Pfister
Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes
Hermann Haller
Rhythmologische und metabolische Kontrolle
Denise Guckel, Christian Sohns, Philipp Sommer
Lipidsenkung: neue Substanzen und neue Konzepte
Julia Brandts, Marlo Verket, Dirk Müller-Wieland
Herz und Diabetes
Martin Berger, Constance C. F. M. J. Baaten, Heidi Noels, Nikolaus Marx, Katharina Schütt
Diabetes, heart failure, and myocardial revascularization: Is there a new message from the ISCHEMIA trial?
Franz-Josef Neumann
First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study
Ali Rıza Akyüz, Ali Hakan Konuş, Ömer Faruk Çırakoğlu, Sinan Şahin, Selim Kul, Levent Korkmaz
Association of CHA2DS2-VASc score with thrombus burden in patients with acute myocardial infarction undergoing SVG-PCI
Orhan Maden, Özge Çakmak Karaaslan, Yücel Kanal, İdris Yakut, Nezaket Merve Yaman, Hasan Can Könte, Kevser Gülcihan Balcı, Mehmet Timur Selçuk, Hatice Selçuk
Assessment of proarrhythmic ventricular electrophysiological remodeling in patients with rheumatoid arthritis
Nazire Aladag, Ahmet Guner, Cagdas Arslan, Ali Kemal Kalkan, Serkan Kahraman, Hicaz Zencirkiran Agus, Nesrin Sen, Mehmet Engin Tezcan, Banu Sahin Yildiz, Mustafa Yildiz
Erratum to: Outcomes of patients with ST-segment myocardial infarction admitted during the COVID-19 pandemic
M. Rattka, C. Winsauer, L. Stuhler, K. Thiessen, M. Baumhardt, T. Stephan, W. Rottbauer, A. Imhof
Management des chronischen Koronarsyndroms
Udo Sechtem, Andreas Seitz, Peter Ong, Raffi Bekeredjian